An interventional study of T1D-CATCH in Diabetes, Type 1 Diabetes and Young Adult, sponsored by Albert Einstein College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Albert Einstein College of Medicine · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Albert Einstein College of Medicine.
Among the 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine, this one has the largest enrollment, is one of 2 that started in 2022, is one of 4 with no phase, and was the 10th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine is open now, in 1 country. Recruiting first, the newest first:
Albert Einstein College of Medicine · Sites in United States
Ages 18–64
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 18 across the 11 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care. The investigators will recruit from adult and pediatric endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.
The study will involve a 9-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities) (YA-URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, New York, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 119 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.
Behavioral: T1D-CATCH
Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.
As defined by the Centers for Disease Control and Prevention (CDC), a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities. CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.
Technology Initiation
Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.
Time frame: Up to 6 months after initiating intervention
Technology Initiation
Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.
Time frame: Up to 3 months after initiating intervention
Continued Technology Use - Percent Use
Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use \>90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.
Time frame: 9 months following intervention
Continued Technology Use - Days of Wear
Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.
Time frame: 9 months following intervention
Feasibility Check
Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility
Time frame: 6 months (post-intervention)
Adoption
Measured by recruitment logs
Time frame: 9 months (post-intervention)
Adoption
Measured by electronic medical records (EMR)
Time frame: 9 months (post-intervention)
Adoption
Measured by young adult participant consent rates
Time frame: 9 months (post-intervention)
Adoption
Measured by percentage of provider opt-in
Time frame: 9 months (post-intervention)
Adoption
Measured by CHW communications
Time frame: 9 months (post-intervention)
Fidelity
Measured by the community health worker (CHW) dashboard
Time frame: Baseline
Fidelity
Measured by electronic medical records (EMR) to analyze session attendance
Time frame: Baseline
Fidelity
Measured by content delivery
Time frame: Baseline
Fidelity
Measured by community health workers (CHW) dashboard
Time frame: 3 month mark
Fidelity
Measured by CHW session recordings
Time frame: 3 month mark
Fidelity
Measured by EMR to analyze session attendance
Time frame: 3 month mark
Fidelity
Measured by content delivery
Time frame: 3 month mark
Fidelity
Measured by insurance tasks
Time frame: 3 month mark
Fidelity
Measured by CHW dashboard
Time frame: 6 month mark
Fidelity
Measured by CHW session recordings
Time frame: 6 month mark
Fidelity
Measured by EMR to analyze session attendance
Time frame: 6 month mark
Fidelity
Measured by content delivery
Time frame: 6 month mark
Fidelity
Measured by insurance tasks
Time frame: 6 month mark
Cost
Measured by time sheets, receipts, and budget to analyze CHW salary/benefits
Time frame: 6 months (post-intervention)
Cost
Measured by time sheets, receipts, and budget to analyze CHW equipment
Time frame: 6 months (post-intervention)
Cost
Measured by time sheets, receipts, and budget to analyze CHW consumables
Time frame: 6 months (post-intervention)
YA-URM Autonomy/ Competence, Social Support
Measured using the Healthcare Self-Determination survey
Time frame: Baseline
YA-URM Autonomy/ Competence, Social Support
Measured using the Healthcare Self-Determination survey
Time frame: 3 month mark
YA-URM Autonomy/ Competence, Social Support
Measured using the Healthcare Self-Determination survey
Time frame: 6 month mark
YA-URM Autonomy/ Competence, Social Support
Measured using the Healthcare Self-Determination survey
Time frame: 9 month mark
Hemoglobin A1c
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Time frame: Baseline
Hemoglobin A1c
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Time frame: 3 month mark
Hemoglobin A1c
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Time frame: 6 month mark
Hemoglobin A1c
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Time frame: 9 month mark
Quality of Life (Diabetes Distress)
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Time frame: Baseline
Quality of Life (Diabetes Distress)
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Time frame: Baseline
Quality of Life (Diabetes Distress)
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Time frame: Baseline
Quality of Life (Diabetes Distress)
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Time frame: Baseline
Quality of Life (Diabetes Distress)
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Time frame: 3 month follow-up
Quality of Life (Diabetes Distress)
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Time frame: 3 month follow-up
Quality of Life (Diabetes Distress)
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Time frame: 3 month follow-up
Quality of Life (Diabetes Distress)
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Time frame: 3 month follow-up
Quality of Life (Diabetes Distress
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Time frame: 6 month follow-up
Quality of Life (Diabetes Distress)
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Time frame: 6 month follow-up
Quality of Life (Diabetes Distress)
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Time frame: 6 month follow-up
Quality of Life (Diabetes Distress)
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Time frame: 6 month follow-up
| Milestone | T1D-CATCH | Usual Endocrine Care Control Condition |
|---|---|---|
| Started | 59 | 60 |
| Completed | 57 | 56 |
| Not completed | 2 | 4 |
| Withdrew: Lost to follow-up | 2 | 4 |
Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.
| Participants | T1D-CATCH | Usual Endocrine Care Control Condition |
|---|---|---|
| Technology Initiation | 36 | 14 |
Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.
| Participants | T1D-CATCH | Usual Endocrine Care Control Condition |
|---|---|---|
| Technology Initiation | 26 | 9 |
Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use \>90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.
Results for this outcome have not been posted.
Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.
Results for this outcome have not been posted.
Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility
Results for this outcome have not been posted.
Measured by recruitment logs
Results for this outcome have not been posted.
Measured by electronic medical records (EMR)
Results for this outcome have not been posted.
Measured by young adult participant consent rates
Results for this outcome have not been posted.
Measured by percentage of provider opt-in
Results for this outcome have not been posted.
Measured by CHW communications
Results for this outcome have not been posted.
Measured by the community health worker (CHW) dashboard
Results for this outcome have not been posted.
Measured by electronic medical records (EMR) to analyze session attendance
Results for this outcome have not been posted.
Measured by content delivery
Results for this outcome have not been posted.
Measured by community health workers (CHW) dashboard
Results for this outcome have not been posted.
Measured by CHW session recordings
Results for this outcome have not been posted.
Measured by EMR to analyze session attendance
Results for this outcome have not been posted.
Measured by content delivery
Results for this outcome have not been posted.
Measured by insurance tasks
Results for this outcome have not been posted.
Measured by CHW dashboard
Results for this outcome have not been posted.
Measured by CHW session recordings
Results for this outcome have not been posted.
Measured by EMR to analyze session attendance
Results for this outcome have not been posted.
Measured by content delivery
Results for this outcome have not been posted.
Measured by insurance tasks
Results for this outcome have not been posted.
Measured by time sheets, receipts, and budget to analyze CHW salary/benefits
Results for this outcome have not been posted.
Measured by time sheets, receipts, and budget to analyze CHW equipment
Results for this outcome have not been posted.
Measured by time sheets, receipts, and budget to analyze CHW consumables
Results for this outcome have not been posted.
Measured using the Healthcare Self-Determination survey
Results for this outcome have not been posted.
Measured using the Healthcare Self-Determination survey
Results for this outcome have not been posted.
Measured using the Healthcare Self-Determination survey
Results for this outcome have not been posted.
Measured using the Healthcare Self-Determination survey
Results for this outcome have not been posted.
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Results for this outcome have not been posted.
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Results for this outcome have not been posted.
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Results for this outcome have not been posted.
Obtained by POC (in clinic) or laboratory (DCA Vantage)
Results for this outcome have not been posted.
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Results for this outcome have not been posted.
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Results for this outcome have not been posted.
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Results for this outcome have not been posted.
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Results for this outcome have not been posted.
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Results for this outcome have not been posted.
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Results for this outcome have not been posted.
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Results for this outcome have not been posted.
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Results for this outcome have not been posted.
Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)
Results for this outcome have not been posted.
Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Results for this outcome have not been posted.
Validated survey: Diabetes Self-Management Questionnaire (DSMQ)
Results for this outcome have not been posted.
Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.
Results for this outcome have not been posted.
Collected over Up to 6 months following initiation of intervention. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T1D-CATCH | 0/59 (0%) | 14/59 (23.7%) | 5/59 (8.5%) |
| Usual Endocrine Care Control Condition | 0/60 (0%) | 24/60 (40%) | 8/60 (13.3%) |
| Event | T1D-CATCH | Usual Endocrine Care Control Condition |
|---|---|---|
| Diabetic KetoacidosisEndocrine disorders | 7/59 | 16/60 |
| Car Accident or AltercationSocial circumstances | 4/59 | 1/60 |
| GastroenteritisGastrointestinal disorders | 3/59 | 4/60 |
| Chest painCardiac disorders | 2/59 | 3/60 |
| Event | T1D-CATCH | Usual Endocrine Care Control Condition |
|---|---|---|
| Stomach painGastrointestinal disorders | 3/59 | 5/60 |
| Eye pain/ConjunctivitisEye disorders | 2/59 | 3/60 |
| Age, Continuous(years) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Mean | 25.0 ± 4.7 | 24.8 ± 4.3 | 24.9 ± 4.5 |
| Sex: Female, Male(Participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Female | 30 | 27 | 57 |
| Male | 29 | 33 | 62 |
| Race/Ethnicity, Customized(Participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Non-Hispanic Black | 17 | 20 | 37 |
| Hispanic | 42 | 40 | 82 |
| Region of Enrollment(participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| United States | 59 | 60 | 119 |
| Primary Insurance(Participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Private | 12 | 11 | 23 |
| Public | 47 | 49 | 96 |
| Education(Participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Some High School | 7 | 4 | 11 |
| High School/General Educational Development (GED) | 21 | 24 | 45 |
| Some College | 22 | 16 | 38 |
| Associate Degree | 3 | 7 | 10 |
| Bachelor's Degree | 4 | 4 | 8 |
| Data Unavailable/Missing | 2 | 5 | 7 |
| Number of Participants with Any Health-Related Social Need(Participants) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Count of participants | 28 | 33 | 61 |
| Diabetes Distress based on Problem Areas in Diabetes-11 (PAID-11) survey(score on a scale) | T1D-CATCH | Usual Endocrine Care Control Condition | Total |
|---|---|---|---|
| Mean | 19 ± 11 | 17 ± 11 | 18 ± 11 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Sep 2025, 34 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 34 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Albert Einstein College of Medicine →